IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Genitourinary Cancer
National Cancer Institute (NCI)protein_peptidePhase 1Active
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Genitourinary Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Spanish Oncology Genito-Urinary Group | Phase 2 | B |
su011248 M.D. Anderson Cancer Center | Phase 2 | B |
Ipilimumab Dana-Farber Cancer Institute | Phase 2 | B |
Atezolizumab British Columbia Cancer Agency | Phase 2 | B |
Riluzole University of California, Irvine | Phase 2 | CCC |
View all 16 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →